mor202
mor202: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Lead developer: GH Research PLC (GHRS)
Development Pipeline (1)
| Company | Phase |
|---|---|
| GH Research PLC (GHRS) | Phase 2 |
Clinical Trials (1)
Rescue Therapy With the Human Anti-CD38 Antibody MOR202 (Felzartamab) in Patients With Membranous Nephropathy Who Failed Anti-CD20 Target Therapy
Frequently asked questions
Who is developing mor202?
mor202 is being developed by GH Research PLC.
How many clinical trials involve mor202?
BioSniper tracks 1 clinical trial involving mor202.
Analyze GH Research PLC & mor202 with AI
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
- 200 free AI credits / month to run live multi-agent analysis
- Watchlist, catalyst alerts & the biotech event calendar
- Full pipeline, financials & FDA data on every company